Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage

Inclusion Criteria: * Age 18 to 80 years; * Spontaneous intracerebral hemorrhage (ICH); * Supratentorial ICH; * Hematoma volume \<30 mL (calculated using the ABC/2 method); * Glasgow Coma Scale (GCS) score \>9 at randomization; * Time from onset to randomization: 48-72 hours; * Patient and/or legal representative provides informed consent. Exclusion Criteria: * Intracerebral hemorrhage attributed to other causes (e.g., cerebral aneurysm, cerebrovascular malformation, brain tumor, cerebral venous sinus thrombosis, hemorrhagic transformation of ischemic stroke, head trauma, anticoagulation therapy, hematologic disorders). * Hemorrhage located in the infratentorial region. * Hemorrhage confined primarily to the ventricular system. * Clinical signs or symptoms suggestive of brain herniation (e.g., progressive decline in level of consciousness, diminished or absent pupillary light reflexes, bilateral pyramidal signs). * Severe cardiac dysfunction (NYHA Class III or IV). * High-risk chronic arrhythmias (e.g., sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia-related syncope without pacemaker implantation). * Severe hepatic impairment defined as ALT \>2x ULN or AST \>2x ULN (ULN = Upper Limit of Normal). * Severe renal impairment defined as serum creatinine \>1.5x ULN. * History of severe asthma or chronic obstructive pulmonary disease (COPD). * History of coagulopathy or systemic bleeding disorder. * Leukopenia (\<2 × 10⁹/L) or thrombocytopenia (\<100 × 10⁹/L). * Patients scheduled for surgical intervention (including, but not limited to, hematoma evacuation \[minimally invasive or conventional\], decompressive craniectomy, hematoma aspiration, or external ventricular drainage) prior to the first dose of study treatment. * Pre-stroke modified Rankin Scale (mRS) score \>2. * Presence of other severe disease resulting in a life expectancy of less than 1 year. * Inability to understand the study procedures and/or complete follow-up due to psychiatric illness, cognitive impairment, or emotional disorders. * Women who are pregnant or lactating. * Participation in another clinical trial within the past 3 months or current participation in another clinical trial.